Agensys a biotechnology company, engages in the research and development of therapeutic human monoclonal antibodies and antibody drug conjugates for the treatment of cancer. It offers products to treat various tumors, as well as prostate, pancreatic, and bladder cancers. The company, formerly known as UroGenesys, was founded in 1997 and is based in Santa Monica, California. As of December 18, 2007, Agensys, Inc. operates as a subsidiary of Astellas Pharma US, Inc.

Research Grants 11 show all






Publications 49 show all

  • 6
  • 5
    Antibodies, Monoclonal/pharmacology
  • 5
  • 4
    Antineoplastic Agents/pharmacology
  • 4
    Immunoglobulin G/chemistry
  • 3
    Antibodies, Monoclonal/chemistry
  • 3
  • 3
  • 2
    Antibodies, Monoclonal, Humanized/chemistry
  • 2
    Antibodies, Monoclonal/metabolism

Patents 1,012show all

  • 501
    C07K - Peptides
  • 434
    A61K - Preparations for medical, dental, or toilet purposes
  • 223
    G01N - Investigating or analysing materials by determining their chemical or physical properties
  • 204
    Y02A - Technologies for adaptation to climate change
  • 164
    C12N - Microorganisms or enzymes
  • 154
    A01K - Animal husbandry
  • 121
    C12Q - Measuring or testing processes involving enzymes, nucleic acids or microorganisms
  • 6
    B01L - Chemical or physical laboratory apparatus for general use
  • 3
    C23C - Coating metallic material
  • 3
    G06Q - Data processing systems or methods, specially adapted for administrative, commercial, financial, managerial, supervisory or forecasting purposes

Clinical Trials 14show all

10Phase 13Phase 21N/A

SEC Filings show all


Contact Information

1545 17th Street
Santa Monica, CA 90404
United States


Total FundingEmployeesLast Funding DateStatus

Crunchbase Investment Rounds

DateAmountRoundValuationLead InvestorOther Investors
2002-03-04$42,800,000Series CBear Stearns, OrbiMed, Alta PartnersReqMed Company, Lombard Odier, Hambrecht & Quist Capital Management, HBM Partners, Carnegie Asset Management
2007-07-12$41,300,000Series DJAFCO Asia, Duquesne Capital ManagementNextech Invest, HBM Healthcare Investments AG, Alta Partners, Tekla Capital Management, OrbiMed, Bear Stearns, Lombard Odier, Innovis Investments
1997-11-10$8,000,000Series A
1999-10-11$11,300,000Series BLombard Odier
2003-03-05$3,000,000Debt FinancingSilicon Valley Bank

SEC Form D Funding Events

2007-07-16Unknown Unknown Other (Paper Filing)